Sickle Cell Disease, Neurocognitive Disorders, Social Participation (SOCIODREP)

This project will promote the development of transdisciplinary analyses. Neuropsychological disorders will be explored with the usual appropriate tests done by psychologists and neuropsychologists regularly involved in the management of sickle cell disease affected children. For the social sciences' component, various methods will be used: Measure of the Life habits (MHAVIE), Measure of Environmental Quality (MQE) and semi-guided interviews will complete the collection of qualitative data. The expected results concern the identification of the barriers or facilitators the sickle cell patients might face in their social participation, whether they are affected or not by neurological disorders.

Study Overview

Status

Completed

Conditions

Detailed Description

Sickle cell anaemia, which is the most frequent genetic disease in France, requires an early and optimal care to reduce its morbidity and mortality. Children with sickle cell anaemia who are significantly anaemic may present neurological complications including stroke with or without clinical signs. A major risk associated to these strokes is the impairment of the general intellectual ability and learning ability, essentially resulting from neuropsychological disorders affecting intellectual functioning, executive and attentional functions. Although the negative impact of sickle cell anemia on the quality of life of the affected children and adolescents is well documented, no study has been focused on the role played by the neurocognitive disorders on their social participation. The objective of this project is the assessment of the influence of neurocognitive disorders in the social participation of children and adolescent with sickle cell anemia (6 to 16 years old), followed in Guadeloupe. This project will promote the development of transdisciplinary analyses. Neuropsychological disorders will be explored with the usual appropriate tests done by psychologists and neuropsychologists regularly involved in the management of sickle cell disease affected children. For the social sciences' component, various methods will be used: Measure of the Life habits (MHAVIE), Measure of Environmental Quality (MQE) and semi-guided interviews will complete the collection of qualitative data. The expected results concern the identification of the barriers or facilitators the sickle cell patients might face in their social participation, whether they are affected or not by neurological disorders

Study Type

Observational

Enrollment (Actual)

134

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • France
      • Pointe-à-Pitre, France, Guadeloupe, 97139
        • CHU de la Guadeloupe

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years to 16 years (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

This study concerns patients with sickle cell anemia, followed by physicians in Guadeloupe.

Description

Inclusion Criteria:

  • Sickle cell anemia
  • Age between 6 and 16 years inccuded, attending the centre of reference for sickle cell disease in Guadeloupe
  • Informed consent
  • Medical insurance

Exclusion Criteria:

  • Other sickle cell syndrome other than SS or Sb-thal
  • Less than 6 years old or older than 16
  • Attending other sickle cell departments
  • No medical insurance

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Case
Children with sickle cell anemia attending the centre of reference for sickle cell disease in Guadeloupe.

Life habits include daily activities and social in 6 groups. Environmental factors include social (9 different subgroups) and physical factors (7 different subgroups).

Personal factors are person related parameters (gender, age, sociocultural ethnic, skills, deficiencies factors,…).

Other Names:
  • Measure of Environmental Quality (MQE)
  • semi-guided interviews
Control
Control children without chronical disease

Life habits include daily activities and social in 6 groups. Environmental factors include social (9 different subgroups) and physical factors (7 different subgroups).

Personal factors are person related parameters (gender, age, sociocultural ethnic, skills, deficiencies factors,…).

Other Names:
  • Measure of Environmental Quality (MQE)
  • semi-guided interviews

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
MHAVIE-Children
Time Frame: Inclusion
Assessment of Life Habits-LIFE-H
Inclusion
MQE
Time Frame: Inclusion
Measure of Environmental Quality (MQE)
Inclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 19, 2018

Primary Completion (Actual)

June 3, 2019

Study Completion (Actual)

June 3, 2019

Study Registration Dates

First Submitted

March 8, 2021

First Submitted That Met QC Criteria

March 9, 2021

First Posted (Actual)

March 11, 2021

Study Record Updates

Last Update Posted (Actual)

March 11, 2021

Last Update Submitted That Met QC Criteria

March 9, 2021

Last Verified

March 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe